Scleroderma: The role of serum autoantibodies in defining specific clinical phenotypes and organ system involvement

Current Opinion in Rheumatology

Volumn 26, Issue 6, 2014, Pages 646-652

  Domsic, Robyn T ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Antibodies; Systemic sclerosis

Indexed keywords

ANTIBODY; AUTOANTIBODY; CENTROMERE ANTIBODY; DNA DIRECTED RNA POLYMERASE III ANTIBODY; DNA TOPOISOMERASE ANTIBODY; FIBRILLARIN; UNCLASSIFIED DRUG;

ANTIBODY TITER; FINGER ULCER; GEOGRAPHIC DISTRIBUTION; INTERSTITIAL LUNG DISEASE; MYOSITIS; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; REVIEW; SCLERODERMA; STOMACH ANTRUM VASCULAR ECTASIA; SYSTEMIC SCLEROSIS; BLOOD; HUMAN; IMMUNOLOGY;

AUTOANTIBODIES; HUMANS; PHENOTYPE; PROGNOSIS; SCLERODERMA, SYSTEMIC;

EID: 84927775196     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000113     Document Type: Review

References (26)

1. LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001; 28:1573-1576.
2. van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 2013; 65:2737-2747.
3. van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis 2013; 72:1747-1755.
4. Kaji K, Fertig N, Medsger TA Jr, et al. Autoantibodies to RuvBL1 and RuvBL2: a novel systemic sclerosis-related antibody associated with diffuse cutaneous and skeletal muscle involvement. Arthritis Care Res 2014; 66:575-584.
5. Betteridge Z, Woodhead F, Bunn C. Anti-EIF2 is associated with interstitial lung disease in patients with systemic sclerosis. Rheumatology 2012; 52 (Suppl 3):34-35.
6. Nikpour M, Hissaria P, Byron J, et al. Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a crosssectional analysis of data from an Australian cohort. Arthritis Res Ther 2011; 13:R211.
7. Sobanski V, Dauchet L, Lefevre G, et al. Prevalence of anti-RNA polymerase III antibodies in systemic sclerosis: new data from a French cohort and a systematic review and meta-analysis. Arthritis Rheumatol 2014; 66:407-417.
8. Meier FM, Frommer KW, Dinser R, et al. Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis 2012; 71:1355-1360.
9. Burgess M, Domsic R, Medsger TA Jr, et al. Gastric antral vascular ectasia in scleroderma: a single center experience. Gastroenterology 2011; 140 (Suppl 1):S-739.
10. Sujau I, Ng CT, Sthaneshwar P, et al. Clinical and autoantibody profile in systemic sclerosis: baseline characteristics from a West Malaysian cohort. Int J Rheum Dis 2014. [Epub ahead of print]
11. Hashimoto A, Endo H, Kondo H, et al. Clinical features of 405 Japanese patients with systemic sclerosis. Mod Rheumatol 2012; 22:272-279.
12. Hasegawa M, Hatta Y, Matsushita T, et al. Clinical and laboratory features dependent on age at onset in Japanese systemic sclerosis. Mod Rheumatol 2013; 23:913-919.
13. Vanthuyne M, Smith V, De Langhe E, et al. The Belgian Systemic Sclerosis Cohort: correlations between disease severity scores, cutaneous subsets, and autoantibody profile. J Rheumatol 2012; 39:2127-2133.
14. Mierau R, Moinzadeh P, Riemekasten G, et al. Frequency of disease-associated and other nuclear autoantibodies in patients of the German Network for Systemic Scleroderma: correlation with characteristic clinical features. Arthritis Res Ther 2011; 13:R172.
15. Gunn J, Pauling JD, McHugh NJ. Impact of anticentromere antibodies on pulmonary function test results in patients with systemic sclerosis without established or suspected pulmonary disease. Clin Rheumatol 2014; 33:869-871.
16. Pakozdi A, Nihtyanova S, Moinzadeh P, et al. Clinical and serological hallmarks of systemic sclerosis overlap syndromes. J Rheumatol 2011; 38:2406-2409.
17. Koschik RW 2nd, Fertig N, Lucas MR, et al. Anti-PM-Scl antibody in patients with systemic sclerosis. Clin Exp Rheumatol 2012; 30 (Suppl 71):S12-S16.
18. Moinzadeh P, Aberer E, Ahmadi-Simab K, et al. Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis. Ann Rheum Dis 2014. [Epub ahead of print]
19. Rodriguez-Reyna TS, Hinojosa-Azaola A, Martinez-Reyes C, et al. Distinctive autoantibody profile in Mexican Mestizo systemic sclerosis patients. Autoimmunity 2011; 44:576-584.
20. Nihtyanova SI, Schreiber BE, Ong VH, et al. Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheumatol 2014; 66:1625-1635.
21. Aggarwal R, Lucas M, Fertig N, et al. Anti-U3 RNP autoantibodies in systemic sclerosis. Arthritis Rheum 2009; 60:1112-1118.
22. Mohile M, Lucas M, Steen VD, et al. Clinical subtype and autoantibodies both help predict pulmonary arterial hypertension, but autoantibodies are stronger predictors of developing secondary pulmonary hypertension. Clin Exp Rheumatol 2014; 32 (Suppl 81):S-21.
23. Shah AA, Rosen A, Hummers L, et al. Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies. Arthritis Rheum 2010; 62:2787-2795.
24. Airo P, Ceribelli A, Cavazzana I, et al. Malignancies in Italian patients with systemic sclerosis positive for anti-RNA polymerase III antibodies. J Rheumatol 2011; 38:1329-1334.
25. Moinzadeh P, Fonseca C, Hellmich M, et al. Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma. Arthritis Res Ther 2014; 16:R53.
26. Joseph CG, Darrah E, Shah AA, et al. Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science 2014; 343:152-157.